Related Experiment Videos
Anticancer therapy as a pediatric pharmacodynamic paradigm.
W E Evans1, M V Relling, J H Rodman
1Pharmaceutical Division, St. Jude Children's Research Hospital, Memphis, Tenn.
Developmental Pharmacology and Therapeutics
|January 1, 1989
Summary
Pediatric cancer drug studies reveal age-related differences in how children process teniposide and methotrexate. These differences impact drug effectiveness and toxicity in treating acute lymphocytic leukemia.
Area of Science:
- Pediatric oncology
- Clinical pharmacology
- Cancer pharmacokinetics
Background:
- Anticancer drugs often have narrow therapeutic indices, balancing efficacy and toxicity.
- Children with cancer require specialized pharmacokinetic and pharmacodynamic studies.
- Understanding drug disposition in pediatric populations is crucial for optimizing treatment.
Purpose of the Study:
- To review pediatric pharmacokinetic and pharmacodynamic studies of specific anticancer drugs.
- To investigate age-related differences in drug disposition in children with cancer.
- To correlate drug disposition with clinical outcomes, including efficacy and toxicity, in pediatric acute lymphocytic leukemia.
Main Methods:
- Analysis of clinical pharmacokinetic studies for teniposide and high-dose methotrexate in pediatric patients.
- Review of pharmacodynamic studies linking drug disposition to clinical effects.
- Focus on children diagnosed with acute lymphocytic leukemia.
Main Results:
- Significant age-related variations in the disposition of teniposide and high-dose methotrexate were observed in children.
- A clear relationship was established between the disposition of these drugs and their clinical efficacy and toxicity.
- These findings highlight the importance of age-specific dosing strategies.
Conclusions:
- Pharmacokinetic and pharmacodynamic variability in children necessitates tailored approaches to anticancer drug therapy.
- Age-dependent drug disposition significantly influences treatment outcomes in pediatric acute lymphocytic leukemia.
- Further research into pediatric cancer drug dosing can improve therapeutic efficacy and minimize toxicity.